Novo Nordisk is asking patients to make a year-long bet on a drug that most of them quit within 12 months.
The Danish pharma company launched a subscription program for its blockbuster weight-loss injection Wegovy on March 31, offering multi-month plans that lower the per-month cost in exchange for a commitment to stay on the drug. The 12-month plan runs $249 a month, compared with $349 for standard monthly billing, a savings of $1,200 annually for patients who complete the full year, according to Novo's announcement. Shorter plans offer smaller discounts: the three-month plan is $329 a month, and the six-month plan is $299 a month.
About 65 percent of patients with obesity stop GLP-1 treatment within a year, CNBC reported, citing a 2025 study. Every discontinuation is a revenue loss and, potentially, a permanent switch to a competitor. The subscription model lowers the monthly out-of-pocket cost while creating switching friction at the same time. Novo is essentially trying to buy adherence.
"This is the first and only subscription program for FDA-approved Wegovy," said Ed Cinca, senior vice president of marketing and patient solutions at Novo Nordisk, in the company's announcement.
The timing reflects competitive pressure. Eli Lilly holds roughly 60 percent of the U.S. branded GLP-1 market, while Novo holds about 39 percent, CNBC reported. Novo's new CEO, Mike Doustdar, who took over in August 2025, has been managing a turnaround that includes a September 2025 workforce reduction of 9,000 employees, roughly 11 percent of the company's global staff, Reuters reported. The subscription is one retention tool in a larger fight against a competitor with a growing oral drug portfolio.
That oral portfolio is the longer-term threat. Eli Lilly's once-daily oral GLP-1 pill orforglipron is expected to receive FDA approval on April 10, 2026 and launch in the second quarter of 2026, with no fasting requirement, unlike oral Wegovy, which must be taken on an empty stomach followed by a 30-minute wait before eating. David Risinger, an analyst at Leerink Partners, expects oral GLP-1s to represent over a third of the obesity drug market as they come online.
Novo also settled a separate dispute that complicated its telehealth distribution. In February 2026, Novo sued Hims & Hers over the telehealth company's sale of compounded GLP-1 copies. The companies resolved the case on March 9, 2026, with Hims agreeing to sell FDA-approved Wegovy and Ozempic at Novo's standard self-pay prices and to stop advertising compounded versions, Reuters reported. Novo's subscription launch later that same month can be read as an attempt to capture patients directly, at committed pricing, before they find another exit.
For patients who stay the full year, the math is favorable. A patient paying $349 monthly for 12 months spends $4,188. Under the 12-month subscription at $249 monthly, the cost drops to $2,988, a $1,200 savings. A patient who discontinues at month four actually pays more under the subscription: $996 versus $996 at the standard rate, plus loses the benefit of continuity. Novo is counting on the promise of savings to carry patients through side effects, injection logistics, and the plateaus that make stopping feel reasonable.
The bigger question is whether the subscription model actually changes behavior or simply locks in revenue before a more convenient oral option arrives. Novo cut its standard monthly self-pay price to $349 in November from $499, a 30 percent reduction that made the drug more accessible on a monthly basis. The subscription layers an annual commitment on top of that lower floor, improving the economics of staying without changing the underlying reasons patients quit. Whether that is a genuine adherence tool or a revenue-protection mechanism will depend on what happens when orforglipron reaches patients.
The program is available for oral Wegovy as well. The pill costs $249 a month on the 12-month plan, down from the standard $299 monthly price, Novo said. Wegovy is accessible through more than 70,000 U.S. pharmacies and Novo's own pharmacy channel, the company said.
